Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Combination therapy in dyslipidemia: where are we now?

Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM.

Atherosclerosis. 2014 Nov;237(1):319-35. doi: 10.1016/j.atherosclerosis.2014.09.026. Epub 2014 Sep 30.

PMID:
25299967
2.

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

Santos RD.

Atheroscler Suppl. 2014 Sep;15(2):19-25. doi: 10.1016/j.atherosclerosissup.2014.07.003.

PMID:
25257073
3.

Diabetic dyslipidemia.

Wu L, Parhofer KG.

Metabolism. 2014 Dec;63(12):1469-79. doi: 10.1016/j.metabol.2014.08.010. Epub 2014 Aug 29. Review.

PMID:
25242435
4.

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.

Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA.

Ann Intern Med. 2014 Apr 1;160(7):468-76. doi: 10.7326/M13-2526. Review.

PMID:
24514899
5.

Critical review of non-statin treatments for dyslipoproteinemia.

Pang J, Chan DC, Watts GF.

Expert Rev Cardiovasc Ther. 2014 Mar;12(3):359-71. doi: 10.1586/14779072.2014.888312. Epub 2014 Feb 10. Review.

PMID:
24506448
6.

Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia?

Zou X, Si QJ.

J Geriatr Cardiol. 2013 Dec;10(4):349-54. doi: 10.3969/j.issn.1671-5411.2013.04.014.

7.

Cardiometabolic impact of non-statin lipid lowering therapies.

Goyal P, Igel LI, LaScalea K, Borden WB.

Curr Atheroscler Rep. 2014 Feb;16(2):390. doi: 10.1007/s11883-013-0390-0. Review.

PMID:
24395391
8.

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].

Bajnok L.

Orv Hetil. 2014 Jan 12;155(2):62-8. doi: 10.1556/OH.2014.29797. Review. Hungarian.

PMID:
24389322
9.

Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

Hamilton SJ, Watts GF.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):191-203. doi: 10.1900/RDS.2013.10.191. Epub 2013 Aug 10. Review.

10.

A young male with familial hypercholesterolemia.

Rahman A, Ahmed MU, Islam AK, Karim A, Sarker SA.

J Saudi Heart Assoc. 2012 Oct;24(4):261-4. doi: 10.1016/j.jsha.2012.06.264. Epub 2012 Aug 4.

11.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM.

J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

12.

Pharmacotherapies for lipid modification: beyond the statins.

Gotto AM Jr, Moon JE.

Nat Rev Cardiol. 2013 Oct;10(10):560-70. doi: 10.1038/nrcardio.2013.117. Epub 2013 Aug 20. Review.

PMID:
23959229
13.

Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.

Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW.

J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037.

14.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

15.

Role of colesevelam in combination lipid-lowering therapy.

Jones MR, Nwose OM.

Am J Cardiovasc Drugs. 2013 Oct;13(5):315-23. doi: 10.1007/s40256-013-0037-0. Review.

16.

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.

Lee P, Hegele RA.

Expert Opin Investig Drugs. 2013 Nov;22(11):1411-23. doi: 10.1517/13543784.2013.822485. Epub 2013 Jul 26. Review.

PMID:
23889692
17.

Beyond statins: lipid management to reduce cardiovascular risk.

Schuck RN, Mendys PM, Simpson RJ Jr.

Pharmacotherapy. 2013 Jul;33(7):754-64. doi: 10.1002/phar.1268. Epub 2013 Apr 18. Review.

PMID:
23606278
18.
19.

HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.

Lee EY, Klementowicz PT, Hegele RA, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2013 Mar-Apr;7(2):169-73. doi: 10.1016/j.jacl.2012.10.011. Epub 2012 Nov 17. Review.

PMID:
23415437
20.

Dyslipidemia: management using optimal lipid-lowering therapy.

Ito MK.

Ann Pharmacother. 2012 Oct;46(10):1368-81. doi: 10.1345/aph.1R127. Epub 2012 Oct 2. Review.

PMID:
23032652
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk